Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Publication year range
3.
Injury ; 48(7): 1371-1375, 2017 Jul.
Article in English | MEDLINE | ID: mdl-28377264

ABSTRACT

BACKGROUND: Balconing is the term that has been given to consciously jumping into a swimming pool from a balcony or falling from height while climbing from one balcony to another in hotels during holidays METHOD: A 5 years retrospective study was conducted in a tertiary referral centre for severe trauma in the Balearic Islands, where balconing is endemic. Demographic data such as age, sex, nationality, personal records, alcohol or drug consumption, height of the fall and season of the year were collected. Scales of trauma severity and mortality rates were also included. RESULTS: Most of the patients were males, 45 (97.83%), aged 24.20±5.98years, 28 of them of British nationality (60.87%). In 44 (95.65%) cases, alcohol consumption was present accompanied by other drugs in 17 (36.96%) cases. The mean height of the fall was approximately 3 floors. Only 6 (13.04%) were intentional jumpers whereas 40 (86.96%) fell while trying to reach another balcony. CONCLUSION: Balconing is a new injury mechanism for alcohol-related falls from heights. Alcohol and other drug consumption are almost always involved, so balconing could be addressed as another consequence of alcohol abuse and binge drinking.


Subject(s)
Accidental Falls/statistics & numerical data , Alcohol Drinking/epidemiology , Alcoholic Intoxication/epidemiology , Dangerous Behavior , Multiple Trauma/epidemiology , Psychotropic Drugs/adverse effects , Trauma Centers , Adult , Age Factors , Alcohol Drinking/adverse effects , Alcoholic Intoxication/complications , Female , Holidays , Humans , Injury Severity Score , Male , Multiple Trauma/etiology , Retrospective Studies , Spain/epidemiology , Travel , Young Adult
4.
Cir Esp ; 95(4): 214-221, 2017 Apr.
Article in English, Spanish | MEDLINE | ID: mdl-28400138

ABSTRACT

INTRODUCTION: Cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy (HIPEC) has recently been established as the treatment of choice for selected patients with peritoneal carcinomatosis of colonic origin. Until recently, the simultaneous presence of peritoneal and hepatic dissemination has been considered a contraindication for surgery. The aim of this paper is to analyze the morbidity, mortality and survival of patients with simultaneous peritoneal and hepatic resection with HIPEC for peritoneal carcinomatosis secondary to colon cancer. METHODS: Between January 2010 and January 2015, 61 patients were operated on, 16 had simultaneous peritoneal and hepatic dissemination (group RH+), and 45 presented only peritoneal dissemination (group RH-). RESULTS: There were no differences between the groups in terms of demographic data, length of surgery and extension of peritoneal disease. Postoperative grade III-V complications were significantly higher in the RH+ group (56.3 vs. 26.6%; P=.032). For the whole group, mortality rate was 3.2% (two patients in group RH-, and none in group RH+). Patients with liver resection had a longer postoperative stay (14.4 vs. 23.1 days) (P=.027). Median overall survival was 33 months for RH-, and 36 for RH+ group. Median disease-free survival was 16 months for RH-, and 24 months for RH+ group. CONCLUSIONS: Simultaneous peritoneal cytoreduction and hepatic resection resulted in a significantly higher Clavien grade III-V morbidity and a longer hospital stay, although the results are similar to other major abdominal interventions. The application of multimodal oncological and surgical treatment may obtain similar long-term survival results in both groups.


Subject(s)
Colonic Neoplasms/pathology , Cytoreduction Surgical Procedures , Hepatectomy , Hyperthermia, Induced , Liver Neoplasms/secondary , Liver Neoplasms/surgery , Peritoneal Neoplasms/secondary , Peritoneal Neoplasms/therapy , Combined Modality Therapy , Female , Humans , Liver Neoplasms/mortality , Male , Middle Aged , Peritoneal Neoplasms/mortality , Postoperative Complications/epidemiology , Retrospective Studies , Survival Rate
5.
Cir. Esp. (Ed. impr.) ; 95(4): 214-221, abr. 2017. tab, graf
Article in Spanish | IBECS | ID: ibc-162257

ABSTRACT

INTRODUCCIÓN: La citorreducción con quimioterapia intraperitoneal hipertérmica (HIPEC) se ha postulado como tratamiento de elección en pacientes seleccionados con carcinomatosis peritoneal por cáncer de colon. La presencia simultánea de diseminación peritoneal y hepática ha sido considerada una contraindicación para esta cirugía. El objetivo del presente estudio es analizar la morbimortalidad y supervivencia de los pacientes con carcinomatosis peritoneal por cáncer de colon, intervenidos mediante una citorreducción peritoneal y resección hepática simultánea con HIPEC. MÉTODOS: Entre enero de 2010 y enero de 2015 se intervinieron 61 pacientes, 45 pacientes con carcinomatosis peritoneal (grupo RH−) y 16 con carcinomatosis peritoneal y metástasis hepáticas (grupo RH+). RESULTADOS: No hubo diferencias significativas entre los 2grupos en los datos demográficos, ASA, duración de la intervención, ni extensión de la enfermedad peritoneal. Las complicaciones postoperatorias Clavien III-V fueron significativamente superiores en el grupo RH+ (56,3 vs. 26,6%; p = 0,03). La mortalidad global de la serie fue del 3,2% (2 pacientes en el grupo RH− y ninguno en el grupo RH+). Los pacientes con resección hepática presentaron una estancia hospitalaria significativamente más larga (14,4 vs. 23,1 días; p = 0,027). La mediana estimada de supervivencia global fue de 33 meses para RH− y de 36 meses para RH+, y la de supervivencia libre de enfermedad fue de 16 meses para RH− y de 24 para RH+. CONCLUSIONES: La citorreducción peritoneal con resección hepática simultánea presenta una morbilidad postoperatoria y una estancia hospitalaria significativamente mayores, aunque las cifras son similares a las de otras cirugías abdominales mayores. La aplicación de un tratamiento oncológico y quirúrgico multimodal permite obtener resultados de supervivencia similares en ambos grupos


INTRODUCTION: Cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy (HIPEC) has recently been established as the treatment of choice for selected patients with peritoneal carcinomatosis of colonic origin. Until recently, the simultaneous presence of peritoneal and hepatic dissemination has been considered a contraindication for surgery. The aim of this paper is to analyze the morbidity, mortality and survival of patients with simultaneous peritoneal and hepatic resection with HIPEC for peritoneal carcinomatosis secondary to colon cancer. METHODS: Between January 2010 and January 2015, 61 patients were operated on, 16 had simultaneous peritoneal and hepatic dissemination (group RH+), and 45 presented only peritoneal dissemination (group RH−). RESULTS: There were no differences between the groups in terms of demographic data, length of surgery and extension of peritoneal disease. Postoperative grade III-V complications were significantly higher in the RH+ group (56.3 vs. 26.6%; P=.032). For the whole group, mortality rate was 3.2% (two patients in group RH−, and none in group RH+). Patients with liver resection had a longer postoperative stay (14.4 vs. 23.1 days) (P=.027). Median overall survival was 33 months for RH−, and 36 for RH+ group. Median disease-free survival was 16 months for RH−, and 24 months for RH+ group. CONCLUSIONS: Simultaneous peritoneal cytoreduction and hepatic resection resulted in a significantly higher Clavien grade III-V morbidity and a longer hospital stay, although the results are similar to other major abdominal interventions. The application of multimodal oncological and surgical treatment may obtain similar long-term survival results in both groups


Subject(s)
Humans , Hepatectomy/methods , Peritoneal Neoplasms/surgery , Carcinoma/surgery , Cytoreduction Surgical Procedures/methods , Colonic Neoplasms/surgery , Indicators of Morbidity and Mortality , Survival Rate , Neoplasm Metastasis , Infusions, Parenteral , Antineoplastic Agents/administration & dosage
SELECTION OF CITATIONS
SEARCH DETAIL
...